Camstar, the leading provider of enterprise manufacturing execution and quality management solutions, announced today that Favrille, a biopharmaceutical company developing patient-specific cancer immunotherapies, has selected Camstar’s manufacturing execution system (MES), InSite, to replace the company’s current paper-driven batch records to streamline processes.

Favrille is currently in Phase III clinical trials for FavId®, an active immunotherapy for the treatment of follicular B-cell non-Hodgkin’s lymphoma. As the company moves toward commercialization of this product, it is focusing on the implementation of Electronic Batch Records to help scale manufacturing efforts.

Read The Complete Article >>